Valategrast is a potent and orally active dual antagonist of integrin α4β1 (VLA-4) and α4β7, with the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment.

Valategrast contains a common L-phenylalanine-N-aroyl group in which carboxylic acids are responsible for metal ion binding in metal ion-associated adhesion sites (MIDAS)[2].

220847-86-9

C30H32Cl3N3O4

604.95

R-411 free base;Valategrast

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years